Last updated: February 22, 2026
What is NDC 69452-0364?
NDC 69452-0364 corresponds to a specific medication listed under the National Drug Code system. Based on publicly available data, this code matches Immunoglobulin (IGIV) 10%, used for immunodeficiency treatments, autoimmune disorders, and certain neuromuscular conditions.
Market Size and Demand
Current Market Overview
| Parameter |
Data |
| Estimated global immunoglobulin market valuation (2023) |
$14.3 billion (source: EvaluatePharma) |
| Growth rate (CAGR 2023-2028) |
6.8% |
| Major regions |
North America, Europe, Asia-Pacific |
Key Drivers
- Rising prevalence of primary immunodeficiency diseases (PID)
- Expansion of approved indications for IGIV
- Aging populations increasing demand for immunoglobulin therapies
- Limited competition with a few dominant manufacturers
Leading Manufacturers
| Company |
Market Share (%) |
Notable Products |
| CSL Behring |
~50 |
Privigen, Hizentra |
| Grifols |
~25 |
Flebogamma, Gamunex-C |
| Takeda (formerly Shire) |
~15 |
IgRodIG, KIOVIG |
| Other manufacturers |
~10 |
Numerous regional players |
Market Trends
- Growing adoption of subcutaneous immunoglobulin (SCIG) formulations
- Increased outpatient administration
- Focus on reducing infusion frequency and improving patient convenience
Price Analysis
Historical Pricing Metrics
- Privigen (CSL Behring): Approximate wholesale acquisition cost (WAC) in 2023 is $4,600–$5,300 per 5 g vial, translating to ~$920–$1,060 per gram.
- Gamunex-C (Grifols): Similar pricing, $4,500–$5,200 per 5 g vial.
- Hizentra (CSL Behring), a SCIG product: roughly $4,300–$4,800 per 5 g vial.
Price Projections
| Year |
Projected Price per Gram |
Assumptions |
| 2024 |
$950–$1,100 |
Stabilization of supply chains, inflation control |
| 2025 |
$950–$1,200 |
Potential price increases due to raw material costs |
| 2026 |
$1,000–$1,250 |
Continued demand growth, patent considerations |
Factors Influencing Price Trends
- Supply chain stability: shortages or disruptions could elevate prices
- Raw material costs: particularly plasma procurement, which accounts for approximately 70% of production costs
- Regulatory actions and pricing policies, especially in the U.S. and Europe
- Competitive dynamics: entrance of biosimilar or alternative therapies could pressure prices
Regulatory and Policy Environment
- U.S.: Centers for Medicare & Medicaid Services (CMS) controls some pricing through Part B and Part D reimbursement structures.
- Europe: National pricing and reimbursement policies result in significant variation across countries.
- Global: Industry trends toward pricing transparency and value-based agreements.
Potential Market Entry and Competition
Given the existing market dominance by CSL Behring and Grifols, entry requires:
- Competitive pricing strategies
- Demonstration of superior efficacy or safety
- Navigating complex regulatory pathways for biosimilars and generics
Emerging biosimilars are anticipated around 2025–2027, which could influence pricing and market share dynamics.
Summary
- The immunoglobulin market, including NDC 69452-0364, is projected to grow at a 6.8% CAGR through 2028.
- Pricing remains stable but could escalate due to rising raw material costs and supply limitations.
- Major players control approximately 90% of the market, with potential for biosimilar entry by 2025.
- Market expansion driven by increasing demand for immunoglobulin therapies in both primary immunodeficiency and autoimmune diseases.
Key Takeaways
- NDC 69452-0364 represents a high-value, specialized biologic with a large and growing global demand.
- The market is consolidating with dominant players, but biosimilar competition is imminent.
- Prices are expected to remain around $950–$1,200 per gram over the next two years, barring supply disruptions or policy changes.
- Entry requires significant investment, regulatory approval, and a clear differentiation strategy.
- Pricing and supply chain stability will dictate profit margins and market share growth.
FAQs
Q1: How will biosimilars affect the price of NDC 69452-0364?
A: Biosimilars entering the market around 2025–2027 are likely to exert downward pressure on prices, potentially reducing costs by 20–40% depending on market acceptance.
Q2: What are primary factors influencing supply chain stability for immunoglobulin?
A: Plasma collection availability, donor contribution variability, manufacturing capacity, and regulatory constraints.
Q3: Are there emerging indications that could expand the market?
A: Yes. Currently approved for immunodeficiency and autoimmune disorders, research into neurodegenerative diseases and other conditions could increase demand.
Q4: How do reimbursement policies impact pricing in the U.S.?
A: Medicare and private insurers’ reimbursement policies influence net prices, with CMS pushing toward value-based agreements that could constrain pricing growth.
Q5: What are the key regulatory challenges for new entrants?
A: Demonstrating biosimilarity, establishing manufacturing standards, and navigating complex approval pathways for biologics.
Sources:
- EvaluatePharma. (2023). Global immunoglobulin market report.
- IQVIA. (2023). Biologics Market Report.
- FDA. (2022). Biologics approval processes.
- European Medicines Agency. (2023). Regulatory guidelines for biosimilars.
- Health Economics. (2023). Pricing trends in biological therapeutics.
